About this trial
Adagrasib is a targeted therapy designed to target KRAS G12C to help fight specific proteins that help cause tumors to grow and spread throughout the body. It is already approved for use in Europe for patients whose disease has progressed after at least one prior systemic therapy. This trial will evaluate the efficacy, safety, and tolerability of adagrasib in previously untreated patients.
Patient Profile
Patients with previously untreated, locally advanced or metastatic non-squamous non-small cell lung cancer with KRAS G12C mutation
Where’s this trial being run?
Beaumont Hospital, Cork University Hospital, St James’s Hospital, and Mater Private Hospital
Can I join this study / trial?
The first step we recommend is to talk to your doctor or the cancer trials team at your hospital. You can find contact details for cancer trials research units in Ireland here.
It’s also a good idea to print this page and bring it with you to your appointment. It can help guide the conversation and remind you of what to ask. You may also want to talk to your family or friends about your options, as they can offer support as you make decisions.
For more detailed information
Click HereQuestions?
Here’s a list of questions you may have for your doctor or local cancer research team.
QuestionsSummary Data
| Name: | KRYSTAL-4 (CA239-0004 ) |
|---|---|
| Number: | 25-22 |
| Full Title: | A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4) |
| Principal Investigator: | Prof Jarushka Naidoo |
|---|---|
| Type: | Industry Sponsored |
| Sponsor: | BMS |
| Recruitment Started: |
Global: April 2025 Ireland: June 2025 |
| Global Recruitment Target: | 630 |
|---|---|
| Ireland Recruitment Target: | 13 |